Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report issued on Friday. The brokerage set a “hold” rating on the stock.
Trinity Biotech Stock Performance
TRIB opened at $0.76 on Friday. The stock’s 50 day simple moving average is $0.86 and its 200-day simple moving average is $1.43. The stock has a market cap of $13.72 million, a PE ratio of -0.34 and a beta of 1.03. Trinity Biotech has a 1 year low of $0.74 and a 1 year high of $3.55.
Hedge Funds Weigh In On Trinity Biotech
An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its holdings in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 359,810 shares of the company’s stock after purchasing an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned approximately 4.72% of Trinity Biotech worth $390,000 at the end of the most recent quarter. 78.97% of the stock is currently owned by institutional investors and hedge funds.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Featured Stories
- Five stocks we like better than Trinity Biotech
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- Insider Trading – What You Need to Know
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What is the NASDAQ Stock Exchange?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
